ROUNDUP: IDEXX Laboratories Boost FY26 Outlook

What happened

IDEXX Laboratories raised its fiscal 2026 earnings and revenue outlook while reporting third-quarter results. It now expects earnings of $14.96 to $15.16 per share and revenue of $4.741 billion to $4.767 billion, citing acquisition impacts and strong recurring revenue from CAG Diagnostics.

Confirmed

Global impact / market context

Higher guidance signals that management expects stronger full-year results, supported by acquisitions and recurring diagnostics revenue. If those drivers continue, they could lift sales and earnings; if they weaken, the company may have less room to meet its new targets, affecting investor expectations.

Analyst inference

The article reports that IDXX was down 1.31 percent in Monday pre-market trading despite the higher outlook. That shows the guidance increase had not coincided with a price gain at that point, but the article gives no reason for the decline.

Confirmed

What to watch

1. Compare upcoming reported revenue and earnings with the new fiscal 2026 ranges to see whether results are tracking management’s higher expectations. Analyst inference
2. Watch recurring revenue from CAG Diagnostics, which the article identifies as a source of strength, for evidence that this support continues. Analyst inference
3. Track whether acquisition impacts contribute to the outlook as expected; the article does not specify their size or how much they add to revenue or earnings. Analyst inference

Evidence

• Original source link unavailable